Conference item
Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 136.8KB, Terms of use)
-
- Publisher copy:
- 10.1136/annrheumdis-2018-eular.1997
Authors
- Publisher:
- BMJ Publishing Group
- Host title:
- Annals of the Rheumatic Diseases
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 77
- Issue:
- Issue Suppl 2
- Pages:
- 973-974
- Publication date:
- 2018-06-12
- Event location:
- Chicago, Illinois
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
- Pubs id:
-
pubs:922557
- UUID:
-
uuid:765edf14-c4b4-4459-a576-8ac2c51ab184
- Local pid:
-
pubs:922557
- Source identifiers:
-
922557
- Deposit date:
-
2018-10-01
- ARK identifier:
Terms of use
- Copyright holder:
- BMJ Publishing Group Limited
- Copyright date:
- 2018
- Notes:
- © 2018, Published by the BMJ Publishing Group Limited. This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at: 10.1136/annrheumdis-2018-eular.1997. This abstract was presented at the American College of Rheumatology Annual Meeting 2018.
If you are the owner of this record, you can report an update to it here: Report update to this record